On September 2, 2026, Indaptus Therapeutics is trading at $1.20, up +6.19%, after announcing an amended and restated at-the-market offering allowing up to $100 million in common-stock sales through H.C. Wainwright.
- The financing expands potential development funding.
- Future share issuance creates dilution risk.
- Biotechnology sentiment is supportive, with the sector higher during regular trading.